December 16, 2009 (FinancialWire) (Investrend Broadcast Syndicate) — CytRx Corp. (NASDAQ: CYTR) webcast their Lippert/Heilshorn Life Sciences Conference presentation yesterday. A recording of that presentation is now available (via http://infoescrow.net/f/?u=http://www.investorcalendar.com/IC/ClientPage.asp?ID=153293).

CytRx Corporation, a biopharmaceutical research and development company, engages in the development of human therapeutics. Its product pipeline includes Tamibarotene, a synthetic retinoid in Phase II clinical development to treat acute promyelocytic leukemia; INNO-2006, a pro-drug for doxorubicin in Phase II clinical development for the treatment of cancer; Bafetinib, a drug in Phase I clinical development to treat chronic myeloid leukemia; Arimoclomol, an orally-administered small-molecule product candidate in Phase IIb clinical development for the treatment of amyotrophic lateral sclerosis; and Iroxanadine, an orally-administered small-molecule product candidate in Phase I clinical development to treat diabetic ulcers. The company also engages in developing treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology; and new-drug discovery research utilizing its master chaperone regulator assay technology. The company was founded in 1985 and is headquartered in Los Angeles, California.

The company’s current market capitalization is approximately US$ 128.4 million. CYTR’s stock last closed at US$ 1.18 per share.

Other recently webcast company presentations, financial results & earnings calls now available through VCall/WILink include LocatePLUS Holdings, Inc. (OTC: LPHC), Rentech, Inc. (AMEX: RTK), Santarus, Inc. (NASDAQ: SNTS) and ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX). Recordings are accessible via the search function at http://infoescrow.net/f/?u=http://www.investorcalendar.com by entering any company’s ticker symbol into the search field.

Recently issued annual reports and company filings available through WILink (http://investrend.ar.wilink.com/?level=279) include Niusule Biotech Corp. (OTCBB: NIUS), JPMorgan European Investment Trust PLC (LSE: JFF), Ecofin Water & Power Opportunities PLC (LSE: ECWO), Invesco Property Income Trust Ltd. (LSE: IPI), Hansa Trust PLC (LSE: HAN) (OTC: FSBTF), Perpetual Income & Growth Investment Trust PLC (LSE: PLI), New India Investment Trust PLC (LSE: NII), JPMorgan Fleming Smaller Japanese Companies Investment Trust PLC (LSE: JPS), Edinburgh Investment Trust PLC (LSE: EDIN) (OTC: EHITF) and Armour Group PLC (LSE: AMR).

(Source for company description: CytRx Corp.)

FinancialWire(tm) provides complete, daily conference call schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “Daily FirstAlert(tm)” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php).  Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[wreiq] [wbcstsc] [wilnknli]